Cover Image

Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review

IntroductionTuberculosis (TB) spondylitis, also known as Pott's disease, is a severe form of extrapulmonary TB. Infliximab treatment for Crohn's disease (CD) patients increases the risk of TB, and is likely to increase the risk of TB spondylitis as well.Case PresentationWe report a rare ca...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jae Hoon Jung (Author), Sujin Choi (Author), Youra Kang (Author), Dae-Chul Cho (Author), So Mi Lee (Author), Tae In Park (Author), Byung-Ho Choe (Author), Dongsub Kim (Author), Ben Kang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Gummatous cutaneous tuberculosis associated with the use of infliximab for Crohn's disease,
by: Lucas Campos Garcia, et al.
Published: (2021)

Efficacy and safety of oral sulfate tablet vs. polyethylene glycol and ascorbate for bowel preparation in children
by: Sujin Choi, et al.
Published: (2024)

Metastatic Crohn's disease despite infliximab therapy
by: Sara Campos, et al.
Published: (2017)

Infliximab-induced intertriginous psoriasis in patient with Crohn's desease
by: Federica Mola, et al.
Published: (2011)

Profile of infliximab in the treatment of pediatric Crohn’s disease
by: Kierus J, et al.
Published: (2015)

The impact of medication belief on adherence to infliximab in patients with Crohn's disease
by: Shuyan Li, et al.
Published: (2023)

Early intestinal obstruction after infliximab therapy in Crohn's disease
by: Mitsuro Chiba, et al.
Published: (2019)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn's Disease
by: Saeed Razmeh, et al.
Published: (2021)

Change in the treatment strategy for pediatric Crohn's disease
by: Mi Jin Kim, et al.
Published: (2010)

Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries
by: Ben Kang, et al.
Published: (2022)

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn's Disease
by: George Alex, et al.
Published: (2013)

Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile
by: Luz María Medrano, et al.
Published: (2015)

A comparative prognostic performance of definitions of Crohn-like lymphoid reaction in colorectal carcinoma
by: Younghoon Kim, et al.
Published: (2021)

A novel role of the splenic volume in Crohn's disease: evaluating the efficacy of infliximab
by: Xuan Shi, et al.
Published: (2023)

CONTINUOUS INFLIXIMAB THERAPY FOR A 14-YEARS-OLD GIRL WITH CROHN DISEASE
by: E.N. Fedulova, et al.
Published: (2009)

CONTINUOUS INFLIXIMAB THERAPY FOR A 14-YEARS-OLD GIRL WITH CROHN DISEASE
by: E.N. Fedulova, et al.
Published: (2009)

Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection - Reply
by: M. Galeazzi
Published: (2003)

Case Report: Development of Type 1 Autoimmune Pancreatitis in an Adolescent With Ulcerative Colitis Mimicking Pancreatic Cancer
by: Sujin Choi, et al.
Published: (2021)

Tracing the historical foundations of infliximab in Crohn's disease treatment: a cited reference analysis
by: Andy Wai Kan Yeung
Published: (2024)

Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn's disease
by: Kouzhu Zhu, et al.
Published: (2024)

Incidence and Prevalence Trends of Pediatric Inflammatory Bowel Disease in the Daegu-Kyungpook Province From 2017 to 2020
by: Jae Young Choe, et al.
Published: (2022)

Fecal calprotectin as a marker of gastrointestinal involvement in pediatric Henoch-Schönlein purpura patients: a retrospective analysis
by: Eun Young Paek, et al.
Published: (2020)

Erythema dyschromicum perstans (ashy dermatosis) during the treatment with infliximab in a child with Crohn disease
by: Michał Sobjanek, et al.
Published: (2014)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease
by: Beatriz Orts, et al.
Published: (2022)

USE OF COMBINED THERAPY WITH LOCALIZED ADMINISTRATION OF INFLIXIMAB IN CHILDREN WITH CONTINUOUSLY RECURRENT PERIANAL CROHN'S DISEASE
by: O.V. Shcherbakova
Published: (2010)

USE OF COMBINED THERAPY WITH LOCALIZED ADMINISTRATION OF INFLIXIMAB IN CHILDREN WITH CONTINUOUSLY RECURRENT PERIANAL CROHN'S DISEASE
by: O.V. Shcherbakova
Published: (2010)

The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China
by: Wenhui Hu, et al.
Published: (2021)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
by: Toshihiko Kakiuchi, et al.
Published: (2021)

A contact investigation after exposure to a child with disseminated tuberculosis mimicking inflammatory bowel disease
by: Dongsub Kim, et al.
Published: (2018)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN'S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016)

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients
by: Yueying Chen, et al.
Published: (2021)

Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn's Disease
by: Ashley Fonseca, et al.
Published: (2021)

Fecal Microbiota Transplantation is a Promising Switch Therapy for Patients with Prior Failure of Infliximab in Crohn's Disease
by: Qianqian Li, et al.
Published: (2021)

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn's disease
by: Shin Kashima, et al.
Published: (2022)

Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn's disease
by: Kouzhu Zhu, et al.
Published: (2023)

The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn's Disease with Infliximab
by: Marla C. Dubinsky, et al.
Published: (2023)

Infliximab
by: İlgen Ertam Sağduyu
Published: (2022)

Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis
by: Seungwon Yang, et al.
Published: (2021)

Switch from Infliximab to Infliximab-dyyb for Rheumatology Indications
by: Alexi Spoto, et al.
Published: (2021)

Risk factors affecting relapse after discontinuation of biologics in children with Crohn's disease who maintained deep remission
by: Hansol Kim, et al.
Published: (2024)